6 results on '"Freemantle, Sarah J."'
Search Results
2. TRIGGERING ANAPHASE CATASTROPHE TO COMBAT ANEUPLOID CANCERS.
- Author
-
DMITROVSKY, ETHAN, MASANORI KAWAKAMI, XI LIU, FREEMANTLE, SARAH J., and KURIE, JONATHAN M.
- Subjects
ANAPHASE ,ANEUPLOIDY ,CANCER cells ,CELL division ,CYCLIN-dependent kinase inhibitors ,PHOSPHORYLATION ,CENTROSOMES ,LUNG cancer - Abstract
Cancer cells are genetically unstable and often have supernumerary centrosomes. When supernumerary centrosome clustering is inhibited at mitosis, multipolar cell division is forced, triggering apoptosis in daughter cells. This proapoptotic pathway is called anaphase catastrophe. Cyclin-dependent kinase 1 (CDK1) or CDK2 inhibitors can antagonize centrosome clustering and cause anaphase catastrophe to occur in lung cancer and other types of cancer. The centrosome protein CP110, a CDK1 and CDK2 phosphorylation substrate, engages anaphase catastrophe. Intriguingly, CP110 is down regulated by the KRAS oncoprotein, enhancing sensitivity of KRAS-driven cancers to CDK2 inhibitors. Anaphase catastrophe eradicates aneuploid cancer cells while relatively sparing normal diploid cells with two centrosomes. This therapeutic window discriminates between normal and neoplastic cells and can be exploited in the cancer clinic. The work reviewed here establishes that pharmacologically-induced anaphase catastrophe is useful to combat aneuploid cancers, especially when the KRAS oncoprotein is activated. This addresses an unmet medical need in oncology. [ABSTRACT FROM AUTHOR]
- Published
- 2020
3. Evidence for tankyrases as antineoplastic targets in lung cancer.
- Author
-
Busch, Alexander M., Johnson, Kevin C., Stan, Radu V., Sanglikar, Aarti, Ahmed, Yashi, Dmitrovsky, Ethan, and Freemantle, Sarah J.
- Subjects
LUNG cancer ,ADENOMATOUS polyposis coli ,PHOSPHORYLATION ,CANCER cells ,LABORATORY mice - Abstract
Background: New pharmacologic targets are urgently needed to treat or prevent lung cancer, the most common cause of cancer death for men and women. This study identified one such target. This is the canonical Wnt signaling pathway, which is deregulated in cancers, including those lacking adenomatous polyposis coli or β-catenin mutations. Two poly-ADP-ribose polymerase (PARP) enzymes regulate canonical Wnt activity: tankyrase (TNKS) 1 and TNKS2. These enzymes poly-ADP-ribosylate (PARsylate) and destabilize axin, a key component of the β-catenin phosphorylation complex. Methods: This study used comprehensive gene profiles to uncover deregulation of the Wnt pathway in murine transgenic and human lung cancers, relative to normal lung. Antineoplastic consequences of genetic and pharmacologic targeting of TNKS in murine and human lung cancer cell lines were explored, and validated in vivo in mice by implantation of murine transgenic lung cancer cells engineered with reduced TNKS expression relative to controls. Results: Microarray analyses comparing Wnt pathway members in malignant versus normal tissues of a murine transgenic cyclin E lung cancer model revealed deregulation of Wnt pathway components, including TNKS1 and TNKS2. Real-time PCR assays independently confirmed these results in paired normal-malignant murine and human lung tissues. Individual treatments of a panel of human and murine lung cancer cell lines with the TNKS inhibitors XAV939 and IWR-1 dose-dependently repressed cell growth and increased cellular axin 1 and tankyrase levels. These inhibitors also repressed expression of a Wnt-responsive luciferase construct, implicating the Wnt pathway in conferring these antineoplastic effects. Individual or combined knockdown of TNKS1 and TNKS2 with siRNAs or shRNAs reduced lung cancer cell growth, stabilized axin, and repressed tumor formation in murine xenograft and syngeneic lung cancer models. Conclusions: Findings reported here uncovered deregulation of specific components of the Wnt pathway in both human and murine lung cancer models. Repressing TNKS activity through either genetic or pharmacological approaches antagonized canonical Wnt signaling, reduced murine and human lung cancer cell line growth, and decreased tumor formation in mouse models. Taken together, these findings implicate the use of TNKS inhibitors to target the Wnt pathway to combat lung cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
4. Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas.
- Author
-
Yan Ma, Fiering, Steven, Black, Candice, Xi Liu, Ziqiang Yuan, Memoli, Vincent A., Robbins, David J., Bentley, Heather A., Tsongalis, Gregory J., Demidenko, Eugene, Freemantle, Sarah J., and Dmitrovsky, Ethan
- Subjects
DYSPLASIA ,ADENOCARCINOMA ,LUNG cancer ,PROGNOSIS ,CARCINOGENESIS - Abstract
Cyclin E is a critical G
1 -S cell cycle regulator aberrantly expressed in bronchial premalignancy and lung cancer. Cyclin E expression negatively affects lung cancer prognosis. Its role in lung carcinogenesis was explored. Retroviral cyclin E transduction promoted pulmonary epithelial cell growth, and small interfering RNA targeting of cyclin E repressed this growth. Murine transgenic lines were engineered to mimic aberrant cyclin E expression in the lung. Wild-type and proteasome degradation-resistant human cyclin E transgenic lines were independently driven by the human surfactant C (SP-C) promoter. Chromosome instability (CIN), pulmonary dysplasia, sonic hedgehog (Shh) pathway activation, adenocarcinomas, and metastases occurred. Notably, high expression of degradation-resistant cyclin E frequently caused dysplasia and multiple lung adenocarcinomas. Thus, recapitulation of aberrant cyclin E expression as seen in human premalignant and malignant lung lesions reproduces in the mouse frequent features of lung carcinogenesis, including CIN, Shh pathway activation, dysplasia, single or multiple lung cancers, or presence of metastases. This article reports unique mouse lung cancer models that replicate many carcinogenic changes found in patients. These models provide insights into the carcinogenesis process and implicate cyclin E as a therapeutic target in the lung. [ABSTRACT FROM AUTHOR]- Published
- 2007
- Full Text
- View/download PDF
5. A Novel Retinoic Acid Receptor β Isoform and Retinoid Resistance in Lung Carcinogenesis.
- Author
-
Petty, W. Jeffrey, Na Li, Biddle, Adrian, Bounds, Rebecca, Nitkin, Christopher, Yan Ma, Dragnev, Konstantin H., Freemantle, Sarah J., and Dmitrovsky, Ethan
- Subjects
LUNG cancer ,CANCER treatment ,TRETINOIN ,DRUG resistance in cancer cells ,CARCINOGENESIS ,TRANSFORMING growth factors - Abstract
Background: We previously reported that all-trans-retinoic acid (RA) treatment can prevent in vitro transformation of immortalized human bronchial epithelial (HBE) cells. Methods: To determine whether methylation inhibits RARβ expression in HBE cells, we used sodium bisulfite sequencing to compare RARβ P2 promoter methylation patterns in RA-sensitive (BEAS-2B) and RA-resistant (BEAS-2B-R1) HBE cells. Immunoblotting was used to assess induction of the RARβ, placental transforming growth factor β (PTGF-β), Fos-related antigen 1 (Fra-1), and transglutaminase II (TGase II) proteins by RA following treatment with azacitidine, a DNA demethylating agent. The expression, transcriptional activity, and growth suppressive activity of RARβ1′, a novel RAR isoform, were evaluated in lung cancer cells transfected with RARβ1′, and expression was also studied in paired normal lung tissues and lung tumors. All statistical tests were two-sided. Results: Hypermethylation was observed in the 3′ region of the RARβ P2 promoter of BEAS-2B-R1 but not BEAS-2B cells. Azacitidine treatment of BEAS-2B-R1 cells restored RA-inducible RARβ2 and PTGF-β expression but not that of RARβ1′, Fra-1, or TGase II. RARβ1′ expression was repressed in RA-resistant BEAS-2B-R1 cells and in lung cancers, compared with adjacent normal lung tissues. BEAS-2B-R1 cells transiently transfected with RARβ1′ had increased RA-dependent activation of a retinoic acid receptor element (RARE) containing reporter plasmid compared with vector control (mean = 3.2, 95% confidence interval [CI] = 3.1 to 3.3 versus mean = 1.4, 95% CI = 1.3 to 1.5; P«.001). In H358 lung cancer cells transiently transfected with RARβ1′, RA treatment restored target gene expression compared with that in vector-transfected cells and suppressed cell growth compared with that in untreated cells (4 μM; treated mean = 0.49 versus untreated mean = 1.0, difference = 0.51, 95% CI = 0.35 to 0.67, P= .003; 8 μM: treated mean = 0.50 versus untreated mean = 1.0, difference = 0.50, 95% CI = 0.26 to 0.74, P = .015). Conclusion: Restoration of RARβ1′ expression may overcome retinoid resistance in lung carcinogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
6. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors.
- Author
-
Xi Liu, Sempere, Lorenzo F., Haoxu Ouyang, Memoli, Vincent A., Andrew, Angeline S., Yue Luo, Demidenko, Eugene, Korc, Murray, Wei Shi, Preis, Meir, Dragnev, Konstantin H., Hua Li, DiRenzo, James, Bak, Mads, Freemantle, Sarah J., Kauppinen, Sakari, Dmitrovsky, Ethan, Liu, Xi, Ouyang, Haoxu, and Luo, Yue
- Subjects
- *
LUNG cancer , *CARCINOGENESIS , *CANCER cells , *TUMOR suppressor genes , *MESSENGER RNA , *IN situ hybridization - Abstract
MicroRNAs (miRNAs) regulate gene expression. It has been suggested that obtaining miRNA expression profiles can improve classification, diagnostic, and prognostic information in oncology. Here, we sought to comprehensively identify the miRNAs that are overexpressed in lung cancer by conducting miRNA microarray expression profiling on normal lung versus adjacent lung cancers from transgenic mice. We found that miR-136, miR-376a, and miR-31 were each prominently overexpressed in murine lung cancers. Real-time RT-PCR and in situ hybridization (ISH) assays confirmed these miRNA expression profiles in paired normal-malignant lung tissues from mice and humans. Engineered knockdown of miR-31, but not other highlighted miRNAs, substantially repressed lung cancer cell growth and tumorigenicity in a dose-dependent manner. Using a bioinformatics approach, we identified miR-31 target mRNAs and independently confirmed them as direct targets in human and mouse lung cancer cell lines. These targets included the tumor-suppressive genes large tumor suppressor 2 (LATS2) and PP2A regulatory subunit B alpha isoform (PPP2R2A), and expression of each was augmented by miR-31 knockdown. Their engineered repression antagonized miR-31-mediated growth inhibition. Notably, miR-31 and these target mRNAs were inversely expressed in mouse and human lung cancers, underscoring their biologic relevance. The clinical relevance of miR-31 expression was further independently and comprehensively validated using an array containing normal and malignant human lung tissues. Together, these findings revealed that miR-31 acts as an oncogenic miRNA (oncomir) in lung cancer by targeting specific tumor suppressors for repression. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.